Axon Enterprise, Inc $AXON Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC boosted its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 38.4% during the 4th quarter, Holdings Channel reports. The fund owned 137,521 shares of the biotechnology company’s stock after acquiring an additional 38,183 shares during the quarter. ProShare Advisors LLC’s holdings in Axon Enterprise were worth $78,102,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Axon Enterprise by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after acquiring an additional 53,060 shares during the period. Baillie Gifford & Co. increased its stake in Axon Enterprise by 1,198.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after buying an additional 1,516,099 shares during the period. Jennison Associates LLC increased its stake in Axon Enterprise by 53.8% during the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Axon Enterprise by 23.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 838,289 shares of the biotechnology company’s stock valued at $476,089,000 after buying an additional 156,647 shares during the period. Finally, Northern Trust Corp increased its stake in Axon Enterprise by 1.6% during the 3rd quarter. Northern Trust Corp now owns 743,926 shares of the biotechnology company’s stock valued at $533,871,000 after buying an additional 11,726 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO Jennifer H. Mak sold 1,500 shares of Axon Enterprise stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total value of $860,175.00. Following the transaction, the chief accounting officer directly owned 12,240 shares of the company’s stock, valued at $7,019,028. This trade represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Erika Nardini sold 198 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $506.58, for a total transaction of $100,302.84. Following the completion of the transaction, the director directly owned 1,946 shares in the company, valued at approximately $985,804.68. This trade represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,855 shares of company stock valued at $7,109,828 over the last 90 days. 4.20% of the stock is owned by corporate insiders.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $392.34 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $31.62 billion, a price-to-earnings ratio of 157.57, a PEG ratio of 9.39 and a beta of 1.44. The stock’s fifty day simple moving average is $425.17 and its 200 day simple moving average is $508.74. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The business had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company’s quarterly revenue was up 33.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.47 EPS. As a group, sell-side analysts forecast that Axon Enterprise, Inc will post 1.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AXON has been the topic of several research analyst reports. Citizens Jmp lowered their target price on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating on the stock in a research note on Thursday, May 7th. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. Craig Hallum reaffirmed a “buy” rating and issued a $820.00 price objective on shares of Axon Enterprise in a research note on Wednesday, February 25th. Royal Bank Of Canada lowered their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Finally, Robert W. Baird set a $800.00 price objective on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.